UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/538,772	04/07/2006	Atsushi Miyawaki	P28025	6795
	7590 02/02/2009 & BERNSTEIN, P.L.C		EXAMINER	
1950 ROLAND	CLARKE PLACE		LEE, JAE W	
RESTON, VA 20191			ART UNIT	PAPER NUMBER
			1656	
			NOTIFICATION DATE	DELIVERY MODE
			02/02/2009	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

gbpatent@gbpatent.com pto@gbpatent.com Application/Control Number: 10/538,772 Page 2

Art Unit: 1656

Applicants' amendment after final rejection, filed on 01/15/2009, is acknowledged. In the amendment, claim 21 recites a new claim limitation "A polynucleotide encoding a polypeptide comprising the following polypeptide sequences: 1) two sequences of F46L YFP; 2) at least one calmodulin sequence; 3) at least one calmodulin-binding domain of skeletal muscle myosin light chain kinase; and 4) at least one linker sequence comprising 1-30 amino acids," which has not been presented for examination on the merits. Therefore, Applicants' amendment of Claim 21 would introduce new issues that would require further consideration and/or new search if entered because these limitations have yet to be presented for examination on the merits.

Previous rejections of record remain in light of the non-entry of the Applicants' proposed amendment.

/Rebecca E. Prouty/ Primary Examiner, Art Unit 1652